Added value of amyloid PET in individualized risk predictions for MCI patients

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Ingrid S van MaurikWiesje M van der Flier

Abstract

To construct a prognostic model based on amyloid positron emission tomography (PET) to predict clinical progression in individual patients with mild cognitive impairment (MCI). We included 411 MCI patients from the Alzheimer's Disease Neuroimaging Initiative. Prognostic models were constructed with Cox regression with demographics, magnetic resonance imaging, and/or amyloid PET to predict progression to Alzheimer's disease dementia. The models were validated in the Amsterdam Dementia Cohort. The combined model (Harrell's C = 0.82 [0.78-0.86]) was significantly superior to demographics (β = 0.100, P < .001), magnetic resonance imaging (β = 0.037, P = .011), and PET only models (β = 0.053, P = .003).The models can be used to calculate individualized risk, for example, a female MCI patient (age = 60, APOE ε4 positive, Mini-Mental State Examination = 25, hippocampal volume = 5.8 cm3, amyloid PET positive) has 35% (19-57) risk in one year and 85% (64-97) risk in three years. Model performances in the Amsterdam Dementia Cohort were reasonable. The present study facilitates the interpretation of an amyloid PET result in the context of a patient's own characteristics and clinical assessment.

References

Apr 6, 1999·Archives of Neurology·R C PetersenE Kokmen
Dec 17, 2002·NeuroImage·Stephen M SmithNicola De Stefano
Mar 3, 2004·Annals of Neurology·William E KlunkBengt Långström
May 16, 2007·Neurology·C C RoweV L Villemagne
May 29, 2009·Annals of Neurology·David A WolkSteven T De-Kosky
Feb 27, 2010·Annals of Neurology·John C MorrisMark A Mintun
May 18, 2010·Neurobiology of Aging·Christopher C RoweVictor L Villemagne
Oct 12, 2010·Brain : a Journal of Neurology·Clifford R JackUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 1, 2011·NeuroImage·Brian PatenaudeMark Jenkinson
Feb 15, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Abhinay D JoshiUNKNOWN Florbetapir F 18 Study Investigators
Oct 31, 2012·Annals of Neurology·Susan M LandauUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jan 31, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Keith A JohnsonUNKNOWN Amyloid Imaging Taskforce
Aug 21, 2013·Neurobiology of Aging·Paula T TrzepaczUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 8, 2014·Journal of Alzheimer's Disease : JAD·Noora M ScheininJuha O Rinne
Mar 13, 2014·Journal of Alzheimer's Disease : JAD·Wiesje M van der FlierPhilip Scheltens
May 14, 2014·Annual Review of Neuroscience·Jin-Tai YuJohn Hardy
Jun 28, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Kevin T OngChristopher C Rowe
Feb 1, 2013·Neurodegenerative Disease Management·Joshua D GrillJeffrey M Burns
May 20, 2015·JAMA : the Journal of the American Medical Association·Willemijn J JansenHenrik Zetterberg
Jan 1, 2013·Neurodegenerative Disease Management·J Scott RobertsGil D Rabinovici
Mar 1, 2015·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Jing Ming YeoSuvankar Pal
Nov 2, 2016·JAMA Neurology·Marina BoccardiUNKNOWN Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group
Jan 18, 2017·Alzheimer's Research & Therapy·Marissa D ZwanPhilip Scheltens
Feb 9, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Joshua D GrillLiana G Apostolova
Feb 25, 2017·Journal of Alzheimer's Disease : JAD·Simone HollandsUNKNOWN AIBL Research Group
Mar 21, 2017·Neurobiology of Aging·Konstantinos ChiotisUNKNOWN Geneva Task Force for the Roadmap of Alzheimer's Biomarkers
May 6, 2017·Alzheimer's Research & Therapy·Joshua D GrillJason Karlawish
Jul 20, 2017·Lancet Neurology·Giovanni B FrisoniBengt Winblad
Oct 20, 2017·JAMA Neurology·Ingrid S van MaurikUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Oct 27, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Marleen KunnemanEllen M A Smets
Mar 23, 2018·Journal of Alzheimer's Disease : JAD·Wiesje M van der Flier, Philip Scheltens
Apr 15, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Clifford R JackUNKNOWN Contributors
Jul 30, 2018·Alzheimer's Research & Therapy·Arno de WildeWiesje M van der Flier
Oct 20, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Giovanni B FrisoniNicola Raffa

❮ Previous
Next ❯

Citations

Jun 27, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jennifer H LinglerOscar L Lopez
Jan 9, 2021·Alzheimer's Research & Therapy·Ingrid S van MaurikJohannes Berkhof
Sep 19, 2019·Lancet Neurology·Ingrid S van MaurikUNKNOWN Alzheimer's Disease Neuroimaging Initiative

❮ Previous
Next ❯

Methods Mentioned

BETA
Genotyping

Software Mentioned

IDEAS
STATA
AMYPAD
Freesurfer
FMRIBs Integrated ( FSL FIRST )

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.